Since GNAZ is also highly expressed in brain tissue further evaluation of potential cross-reactivity will be necessary (29) to justify clinical application of TCRs 22894-Rac2 and 5934-Rac1 in high-risk patients in order to allow for effective tumor-killing without causing dose-limiting pathology in normal somatic tissues (30). This evidence concerns the gene RAC1 and neoplasm.